Linda Stein Gold, EADV 2022: Tapinarof Cream 1% for the Treatment of Plaque Psoriasis
Tapinarof cream 1% once daily, a topical aryl hydrocarbon receptor (AhR)-modulating agent was recently approved by the FDA for the treatment of plaque psoriasis. touchIMMUNOLOGY were delighted to speak with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) to learn more about the unmet needs in the treatment of plaque psoriasis, the rationale for the use of tapinarof cream 1% in this indication and how the recent FDA approval will impact the treatment paradigm.
The abstract ‘Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials.’ (Abstract number: 1175) was presented at EADV 2022, 7-10 September, 2022.
- What are the unmet needs in the treatment of plaque psoriasis? (0:17)
- What is the mechanism of action of Tapinarof cream 1% and the rationale for its use in plaque psoriasis? (0:51)
- Following FDA approval, where does Tapinarof cream 1% fit in the treatment paradigm for plaque psoriasis? (1:28)
Disclosures: Linda Stein Gold discloses consulting for Dermavant, Arcutis, Leo and Ortho Derm; receiving grant/ research support from Dermavant, Arcutis, Leo and Ortho Derm; serving on advisory boards for Dermavant, Arcutis, Leo and Ortho Derm; receiving honoraria from Dermavant, Arcutis, Leo and Ortho Derm and participating in speaker’s bureaus for Dermavant, Arcutis, Leo and Ortho Derm.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EADV meeting 2022.
Share this Video
Related Videos In Psoriasis
Alan Menter, Dermatology Meeting News 2023: Ixekizumab treatment for patients with moderate-to-severe plaque psoriasis
Ixekizumab is a humanized monoclonal antibody currently approved in patients with moderate-to-severe plaque psoriasis. We caught up with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA) to discuss the aims, design, inclusion criteria and main findings of a post-hoc analysis conducted on trials studying the use of ixekizumab in adult and paediatric patients […]
Alan Menter, Dermatology Meeting News 2023: Clinical presentations and unmet needs of palmoplantar psoriasis
Palmoplantar psoriasis has a significant impact on patients’ quality of life and can be challenging to treat. touchIMMUNOLOGY were delighted to speak with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA), about the prevalence and clinical presentations of palmoplantar psoriasis, its impact on quality of life, and the unmet needs in its treatment. […]
Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis
Deucravacitinib is an allosteric tyrosine kinase 2 inhibitor approved for the treatment of moderate to severe plaque psoriasis, a post-hoc analysis of the phase 3 POETYK PSO-1 and PSO-2 trials investigated the efficacy of deucravacitinib by baseline characteristics in this indication. touchIMMUNOLOGY were delighted to speak with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!